OncLive SOSS

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement - Episode 4

Limitations of Available Treatment Options for Patients with Cardiac Involvement

January 8, 2024

Jeffrey Zonder, MD, Shaji Kumar, MD

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging

EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis

EP. 3: Treatment Approaches in AL Amyloidosis

EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP. 6: Birtamimab Safety Profile in the VITAL Study

EP. 7: Adverse Event Management in AL Amyloidosis

EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis

x